Latest News and Press Releases

Regulated information February 5, 2021 Breda, the Netherlands / Ghent, Belgium — argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people...

Regulated information — Inside information February 4, 2021 Breda, the Netherlands — argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people...

Regulated information — Inside information February 2, 2021, 10:15 PM ESTFebruary 3, 2021, 4:15 AM CET Breda, the Netherlands — argenx SE (Euronext & Nasdaq: ARGX), a global immunology company...

      -No observed elevation of cholesterol markers related to treatment with efgartigimod February 2, 2021 Breda, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), today provided a...

Regulated information — Inside information February 1, 2021 Breda, the Netherlands — argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people...

Regulated Information/Inside Information Independent data monitoring committee confirmed go-forward decision based on evaluation of interim safety as well as efficacy assessments that surpassed...

Submitted Biologics License Application (BLA) to U.S. Food and Drug Administration (FDA) for efgartigimod in generalized myasthenia gravis (gMG)Initiated 50-patient gMG bridging study of...

              Collaboration to expand and accelerate global development of efgartigimod; expected to allow argenx to more rapidly advance new potential indications into clinical development each...

January 4, 2021 Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe...

November 23, 2020 Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe...